BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2349913)

  • 1. Interval treatment of coronary artery disease with sustained-release isosorbide-5-mononitrate.
    Jansen W; Prenze R; Kümper H; Tauchert M
    Am J Cardiol; 1990 Jun; 65(21):16J-22J. PubMed ID: 2349913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow release isosorbide-5-mononitrate therapy in angina pectoris. Effects of exercise performance and hemodynamics.
    Jansen W; Prenzel R; Rappert B; Kümper H; Laufen H; Tauchert M
    Cardiology; 1991; 79 Suppl 2():78-85. PubMed ID: 1760835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)].
    Jansen W; Prenzel R; Kümper H; Weidmann B; Tauchert M
    Z Kardiol; 1989; 78 Suppl 2():72-8; discussion 115-7. PubMed ID: 2511697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.
    Neuhaus R; Johnen R; Vydra L; Solbach C
    Pharmatherapeutica; 1986; 4(8):486-95. PubMed ID: 3086899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
    Thadani U
    Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
    Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
    Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction and circumvention of nitrate tolerance applying different dosage intervals.
    Silber S; Vogler AC; Krause KH; Vogel M; Theisen K
    Am J Med; 1987 Nov; 83(5):860-70. PubMed ID: 3674093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
    Silber S
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S35-51. PubMed ID: 2113003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [4 different nitrate preparations with regard to the possible development of tolerance in long-term treatment].
    Mertens HM; Ohlmeier H; Mannebach H; Kabelitz K; Gleichmann U
    Herz; 1985 Jun; 10(3):172-81. PubMed ID: 3926614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris.
    Seabra-Gomes R; Aleixo AM; Adao M; Machado FP; Mendes M; Bruges G; Palos JL
    Am J Cardiol; 1990 Jun; 65(20):1308-12. PubMed ID: 2188493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and duration of action of isosorbide-5-mononitrate in the treatment of stable angina of effort. Comparison with sustained-release isosorbide dinitrate].
    Lagioia R; Scrutinio D; Mangini SG; De Toma L; Accettura D; De Nicolò M; Saliani P; Preziusi N; Antuofermo F; Rizzon P
    G Ital Cardiol; 1985 Mar; 15(3):299-306. PubMed ID: 4018470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
    Gunasekara NS; Noble S
    Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease.
    Wortmann A; Bachmann K; Meinhold M
    Eur Heart J; 1988 Jan; 9 Suppl A():119-24. PubMed ID: 3409908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of asymmetrical dosage timing of isosorbide-5-mononitrate on nitrate tolerance during long-term administration.
    Hughes LO; DasGupta P; Jain D; Lahiri A; Raftery EB
    Eur J Clin Pharmacol; 1989; 36(2):139-44. PubMed ID: 2498105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris.
    Thadani U; Hamilton SF; Olson E; Anderson JL; Prasad R; Voyles W; Doyle R; Kirsten E; Teague SM
    Am J Cardiol; 1987 Apr; 59(8):756-62. PubMed ID: 3825935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris.
    Wisenberg G; Roks C; Nichol P; Goddard MD
    Am J Cardiol; 1989 Sep; 64(10):569-76. PubMed ID: 2782247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of isosorbide-5-mononitrate on exercise-induced hemodynamic changes in angina pectoris.
    Yokota M; Tsunekawa A; Miyahara T; Kamihara S; Kitamura J; Noda S; Koide M; Tsuzuki M; Sotobata I
    Am J Cardiol; 1986 Jul; 58(1):53-8. PubMed ID: 3728331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease.
    Kenedi P; Gathmann-Lewik U
    Cardiology; 1987; 74 Suppl 1():29-33. PubMed ID: 3300975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.